TechnoPhage, SA is a Biotech company with labs located at the IMM, under a collaboration protocol signed by these two entities. TechnoPhage, SA is engaged in two main R&D programs:

1)    Bacteriophages
R&D of novel products, based on the unique properties of bacteriophages, for the treatment, diagnosis and prevention of bacterial infections. Current work is focused on the R&D of new products targeting nosocomial, community and food industry infections. Different products are being developed with two main purposes:
 a) Specific elimination of antibiotic-resistant bacteria (therapy and sanitation)
 b) Detection and quantification of live microorganisms (diagnostic devices)

2) Recombinant antibodies
R&D on recombinant antibodies with therapeutic and diagnostic applications TechnoPhage, SA continuously strives to increase the number of proprietary products, through an active R&D program and collaboration agreements. TechnoPhage, SA also delivers R&D services for diverse pharmaceutical companies.

 

Director and Chief Executive Officer
Miguel Garcia
www.technophage.pt